Mixed cellularity Hodgkin’s lymphoma, commonly shortened to MCHL or MCCHL, is a subtype of classical Hodgkin lymphoma. The name sounds as though someone spilled an assorted box of cells onto a pathology slide. That description is not entirely wrong: under the microscope, the cancer’s characteristic Hodgkin and Reed-Sternberg cells sit among a varied crowd of lymphocytes, eosinophils, plasma cells, histiocytes, and other inflammatory cells.
Although any cancer diagnosis can make the room feel suddenly smaller, MCHL belongs to one of the most treatable groups of cancers. Modern therapy is selected according to the disease’s stage, symptoms, tumor volume, PET scan findings, age, and overall health rather than the microscopic subtype alone. Many people achieve a lasting remission, including those whose lymphoma is discovered at an advanced stage.
What Is Mixed Cellularity Hodgkin’s Lymphoma?
Hodgkin lymphoma begins in lymphocytes, white blood cells that normally help the immune system recognize and fight infection. Most cases are classified as classical Hodgkin lymphoma, which is divided into four main microscopic subtypes:
- Nodular sclerosis classical Hodgkin lymphoma
- Mixed cellularity classical Hodgkin lymphoma
- Lymphocyte-rich classical Hodgkin lymphoma
- Lymphocyte-depleted classical Hodgkin lymphoma
MCHL is less common in the United States than nodular sclerosis Hodgkin lymphoma, but it remains an important classical subtype. It may occur at any age and is seen relatively often in children, older adults, men, people living with HIV, and populations in regions where Epstein-Barr virus-associated disease is more common. It frequently involves lymph nodes in the upper half of the body, although it may begin elsewhere. Large masses in the center of the chest are generally less typical than they are in nodular sclerosis disease.
Why Is It Called “Mixed Cellularity”?
The term describes the cellular neighborhood surrounding the malignant cells. In classical Hodgkin lymphoma, the actual cancer cells may represent only a small portion of an enlarged lymph node. Much of the swelling comes from noncancerous immune cells recruited by signals released within the tumor microenvironment.
In MCHL, that background is especially diverse. A pathologist may see small lymphocytes, macrophage-like histiocytes, plasma cells, eosinophils, and neutrophils mixed around scattered Hodgkin and Reed-Sternberg cells. Unlike nodular sclerosis disease, broad bands of fibrosis dividing the lymph node into nodules are not the defining feature.
What Reed-Sternberg Cells Reveal
Reed-Sternberg cells are unusually large cells that may contain two prominent nuclei, creating the famous “owl-eye” appearance described in pathology textbooks. Despite losing many normal B-cell characteristics, these malignant cells are believed to originate from B lymphocytes.
Immunohistochemical staining helps confirm the diagnosis. Classical Hodgkin lymphoma cells are strongly positive for CD30, frequently positive for CD15, usually negative for CD45, and often show weak expression of the B-cell marker PAX5. No single marker proves the diagnosis by itself, so the pathologist combines cell appearance, lymph node architecture, staining patterns, and clinical information. A second pathology review may be useful when the specimen is small or the findings are unusual.
Possible Causes and Risk Factors
No single behavior, food, personality trait, or forgotten vitamin causes MCHL. In most people, doctors cannot identify one definite trigger. Researchers instead recognize several factors associated with a higher likelihood of developing Hodgkin lymphoma.
Epstein-Barr Virus
Epstein-Barr virus, or EBV, is the virus that causes infectious mononucleosis. EBV genetic material is found in the malignant cells of some classical Hodgkin lymphomas and is detected more frequently in mixed cellularity tumors than in nodular sclerosis tumors. However, EBV infection is extremely common, while Hodgkin lymphoma is rare. Having had mono does not mean lymphoma is waiting around the corner wearing a tiny villain cape.
Immune System Factors
People with HIV have an increased risk of classical Hodgkin lymphoma, and mixed cellularity disease is disproportionately represented in this population. Other forms of significant immune suppression may also influence lymphoma risk. Treatment plans for a person with HIV generally coordinate lymphoma therapy with effective antiretroviral care and infection prevention.
Age, Sex, and Family History
Hodgkin lymphoma has age-related peaks in early and later adulthood. MCHL is relatively more frequent in older patients and young children than nodular sclerosis disease. Hodgkin lymphoma overall is slightly more common in males, and having a parent, sibling, or child with the disease modestly increases risk. Nevertheless, most patients have no close relative with Hodgkin lymphoma.
Symptoms of Mixed Cellularity Hodgkin’s Lymphoma
The most common warning sign is a painless enlarged lymph node. It may feel like a rubbery lump in the neck, above the collarbone, under an arm, or in the groin. Infections are far more common causes of swollen nodes, but a lump that persists, enlarges, feels firm, or appears without an obvious infection deserves medical evaluation.
Other possible MCHL symptoms include:
- Unexplained fever
- Drenching night sweats
- Unintentional weight loss
- Persistent fatigue or weakness
- Generalized itching without a clear rash
- Reduced appetite
- Abdominal fullness from an enlarged spleen or involved abdominal nodes
- Cough, chest pressure, or shortness of breath when chest nodes are enlarged
Fever, soaking night sweats, and loss of more than 10% of body weight within six months are called B symptoms. The letter B is a staging label, not a grade on how well someone has handled being sick. These symptoms can influence risk classification and treatment planning.
How MCHL Is Diagnosed
Medical History and Examination
The evaluation usually begins with questions about the duration of swollen nodes, fever, sweating, weight changes, itching, infections, medications, and immune conditions. The clinician checks lymph node regions and may examine the abdomen for enlargement of the liver or spleen.
Lymph Node Biopsy
A biopsy is required to diagnose MCHL. When practical, doctors prefer to remove an entire lymph node or a substantial portion of one because Hodgkin lymphoma diagnosis depends on tissue architecture as well as individual cells. A thin needle sample may not collect enough Reed-Sternberg cells or show the surrounding pattern clearly. A core needle biopsy can sometimes be adequate, particularly for a deeply located node, but additional tissue may be needed if the result is uncertain.
Laboratory Testing
Blood tests cannot independently confirm MCHL, but they help evaluate its effects and prepare for treatment. Testing may include a complete blood count, kidney and liver function measurements, inflammatory markers, and screening for infections such as HIV and hepatitis when appropriate. Anemia, a high white blood cell count, a low lymphocyte count, or abnormal inflammatory markers may provide prognostic information, but none is specific to lymphoma.
PET/CT and Other Imaging
FDG-PET combined with CT is central to staging classical Hodgkin lymphoma. Areas using unusually high amounts of glucose appear active on the scan, helping doctors map involved lymph nodes and organs. PET/CT may also be repeated during or after therapy to measure response. Because infections and inflammation can also light up, scan findings must be interpreted in context rather than treated as a glowing yes-or-no oracle.
Depending on the planned medicines, patients may also have an echocardiogram to assess heart function and pulmonary function testing to evaluate the lungs. Fertility preservation should be discussed before treatment when therapy could affect future reproductive options.
Stages of Mixed Cellularity Hodgkin Lymphoma
MCHL is staged in the same way as other classical Hodgkin lymphomas:
- Stage I: One lymph node region or one nearby lymphatic structure is involved.
- Stage II: Two or more lymph node regions are involved on the same side of the diaphragm.
- Stage III: Lymph node regions are involved on both sides of the diaphragm.
- Stage IV: Lymphoma has spread more diffusely into organs outside the lymphatic system, such as the liver, bone marrow, or lungs.
A stage may be followed by A when B symptoms are absent or B when they are present. Doctors also consider bulky disease, the number of nodal areas, extranodal involvement, blood test results, age, and early PET response. Two patients with the same Roman numeral may therefore receive somewhat different recommendations.
Treatment Options for MCHL
MCHL is generally treated according to classical Hodgkin lymphoma guidelines. The mixed cellularity label helps establish the diagnosis, but it rarely chooses the drug regimen by itself. Care is ideally planned by a hematologist-oncologist or multidisciplinary lymphoma team.
Early-Stage Disease
Early favorable disease may be treated with a limited number of chemotherapy cycles, sometimes followed by involved-site radiation therapy. ABVD—doxorubicin, bleomycin, vinblastine, and dacarbazine—has long been a commonly used regimen. Depending on PET response and individual risk, clinicians may adjust the number of cycles, omit bleomycin after an early negative PET scan, or avoid radiation to reduce long-term risks.
Early unfavorable or bulky disease usually requires more treatment than early favorable lymphoma. Radiation can improve local disease control in selected situations, but its potential benefits are balanced against possible future effects on the heart, lungs, thyroid, and risk of second cancers. Modern radiation uses smaller fields and lower doses than older techniques.
Advanced-Stage Disease
For stage III or IV classical Hodgkin lymphoma, systemic treatment is required. On March 20, 2026, the U.S. Food and Drug Administration approved nivolumab combined with doxorubicin, vinblastine, and dacarbazine, known as N-AVD, for previously untreated patients age 12 and older with stage III or IV classical Hodgkin lymphoma.
Other options may include brentuximab vedotin plus AVD, called BV-AVD, or PET-adapted ABVD in selected settings. The choice depends on age, immune conditions, neuropathy risk, lung and heart health, pregnancy considerations, drug access, and patient preferences. Nivolumab activates immune responses against cancer but can also trigger immune-related inflammation. Brentuximab targets CD30 on Hodgkin cells but may cause peripheral neuropathy.
Relapsed or Refractory MCHL
Refractory lymphoma does not respond adequately to initial therapy, while relapsed lymphoma returns after remission. Options may include different chemotherapy combinations, brentuximab vedotin, the checkpoint inhibitors nivolumab or pembrolizumab, radiation in selected areas, or high-dose chemotherapy followed by an autologous stem cell transplant.
The treatment sequence depends heavily on previous therapy, time in remission, transplant eligibility, disease location, and overall health. Clinical trials can provide access to new combinations and cellular or immune-based approaches. A relapse is serious, but it does not eliminate the possibility of another durable remission or cure.
Side Effects and Supportive Care
Common short-term effects of treatment can include fatigue, nausea, constipation, mouth soreness, appetite changes, temporary hair loss, low blood cell counts, infection risk, and changes in taste. Many are preventable or manageable when reported early. There is no prize for silently enduring severe nausea while pretending crackers are a complete personality.
Certain medicines require specific monitoring. Doxorubicin can affect heart function, bleomycin can injure the lungs, brentuximab may cause nerve damage, and checkpoint inhibitors can produce inflammation in organs such as the thyroid, lungs, liver, intestines, skin, or endocrine glands. Patients should follow their oncology team’s instructions about fever, breathing changes, new diarrhea, rash, numbness, chest pain, or other urgent symptoms.
Supportive care may include anti-nausea medicine, infection prevention, growth-factor support, nutrition counseling, physical activity adjusted to energy level, mental health care, and fertility preservation. Patients should discuss supplements with the oncology team because even products marketed as “natural” can interfere with treatment or increase bleeding, liver, or kidney risks.
Outlook and Long-Term Follow-Up
Classical Hodgkin lymphoma is highly treatable, and more than 80% of patients can be cured with current approaches. Outcomes are often even better in early favorable disease. MCHL may be diagnosed with B symptoms or more extensive involvement, but subtype alone does not determine an individual’s prognosis. Stage, treatment response, age, general health, laboratory findings, and PET results are usually more informative.
Follow-up continues after remission because some treatment effects may appear years later. Depending on prior therapy, survivors may need monitoring for thyroid dysfunction, heart or lung problems, fertility changes, bone health concerns, and second cancers. A survivorship care plan should record the exact medicines, doses, radiation fields, recommended screening, and symptoms that warrant evaluation.
When to Seek Medical Care
Arrange a medical evaluation for a persistent or enlarging lymph node, unexplained recurring fever, drenching night sweats, unintended weight loss, severe itching, unusual fatigue, or breathing difficulty. These symptoms often have noncancerous causes, but guessing is not a diagnostic test.
Anyone receiving treatment should contact the oncology team promptly for fever or chills, new shortness of breath, chest pain, uncontrolled vomiting or diarrhea, confusion, unusual bleeding, inability to drink fluids, or other symptoms identified in the personalized treatment instructions.
Conclusion
Mixed cellularity Hodgkin’s lymphoma is a classical Hodgkin lymphoma distinguished by Reed-Sternberg cells surrounded by a varied inflammatory background. It is associated more often than some other subtypes with Epstein-Barr virus, HIV, childhood, and older age, but many patients have none of these factors.
Diagnosis requires a well-interpreted tissue biopsy, while PET/CT, blood testing, symptoms, and disease distribution establish the stage and guide therapy. Chemotherapy remains central, with radiation, targeted treatment, immunotherapy, and stem cell transplantation used according to the clinical situation. Most importantly, MCHL is not defined only by what appears beneath a microscope. It is a highly treatable disease managed with increasingly personalized strategies designed to achieve cure while limiting long-term harm.
A Composite Experience With MCHL: From Suspicion to Survivorship
The following experience is a composite educational illustration based on challenges commonly reported by people undergoing lymphoma evaluation and treatment. It does not describe one identifiable patient and should not be treated as medical advice.
For many people, the experience begins with an ordinary discovery: a lump while shaving, showering, or adjusting a shirt collar. It does not hurt, so ignoring it feels reasonable. A week becomes a month. Perhaps antibiotics are tried, yet the node stays put like a houseguest who has stopped noticing the hint. Fatigue may be blamed on work, while night sweats are blamed on the thermostat. Eventually, persistence wins and an appointment is made.
The period between the first scan and the biopsy result can feel harder than the procedures themselves. New medical words arrive faster than they can be typed into a search bar. “Classical,” “mixed cellularity,” and “Reed-Sternberg” sound technical and frightening, even when the oncologist explains that Hodgkin lymphoma is often curable. Many patients remember only fragments from the first consultation. Bringing another person, taking notes, or asking permission to record the discussion can make the information less slippery.
Staging introduces another emotional hurdle. Hearing “stage III” or “stage IV” may trigger assumptions based on solid tumors, where advanced stages can carry very different implications. The care team explains that advanced classical Hodgkin lymphoma can still be treated with curative intent. That information brings relief, although relief and fear can coexist quite comfortably, like two cats refusing to leave the same chair.
Treatment days gradually develop a rhythm. There may be laboratory tests, a visit with the oncology team, premedications, infusions, and several hours of waiting. Some days are uneventful; others bring nausea, constipation, metallic-tasting food, aching bones, or fatigue that feels heavier than normal sleepiness. Friends may enthusiastically offer elaborate meals when plain toast is the only food that sounds remotely civilized. Learning to state specific needs—a ride, groceries, quiet company, or no visitors—can be more helpful than trying to appear endlessly positive.
The days between treatments can be unpredictable. Energy may improve just before it is time to return for another cycle. A symptom notebook helps distinguish repeating patterns from new problems. Patients often learn that calling the oncology nurse is not “bothering” anyone; it is part of safe care. Questions about fever, shortness of breath, rashes, numb fingers, bowel changes, or medication timing are better handled early than saved for the next scheduled appointment.
An interim PET scan may create a new word for the emotional vocabulary: scanxiety. Waiting for results can make every notification sound ominous. A strong early response is encouraging and may help guide the remaining treatment, but even good news does not instantly erase months of worry. Some people celebrate loudly, while others simply exhale and continue with the next appointment. Both reactions are normal.
When treatment ends, family and friends may expect life to snap back to its previous setting. Survivors often discover that recovery is more gradual. Muscles need rebuilding, sleep may remain irregular, and fear of recurrence can appear before follow-up visits. Returning to work, school, parenting, or exercise may require a phased plan. Counseling, support groups, rehabilitation, and honest conversations with loved ones can help translate “finished treatment” into a sustainable new routine.
Long-term follow-up provides structure. The survivor keeps a record of chemotherapy, immunotherapy, radiation, and major side effects. Routine health care becomes part of cancer care: vaccinations, blood pressure checks, heart-healthy habits, thyroid testing when indicated, recommended cancer screening, dental care, and prompt evaluation of persistent new symptoms. Over time, appointments may become less frequent, and lymphoma may take up less mental space. It remains part of the person’s history, but it no longer has to be the headline of every day.